| Novartis moves SC against Glivec order | 29-AUG-09 |
|
| Swiss drug major Novartis has approached the Supreme Court against a decision of the country’s apex patent complaint redressal forum, the Intellectual Property Appellate Board (IPAB), to deny patent protection for its cancer medicine, Glivec. |
|
|
|
| Novartis loses battle for cancer drug patent | 05-JUL-09 |
|
| Novartis’s famed cancer drug, Glivec, will not get patent protection in India. The apex body on patent and trademark disputes, the Intellectual Property Appellate Board (IPAB), has ruled that the drug “lacks innovation” and the high price tag of Rs 1,20,000 per month per patient would be too high for the common man. “Any patent granted to support such a high monopoly price would be against ‘public order’,” the ruling said. |
|
|
|
|
|
|
| Glivec final hearing from Nov 17 | 05-NOV-08 |
|
| The high profile legal battle over patent rights of Glivec, a blockbuster cancer drug from the stables of Swiss pharma major Novartis, will enter its final phase on November 17.
The Intellectual |
|
|
|
| Apex court wants expert member on patent board | 04-SEP-08 |
|
| The Supreme Court on Tuesday suggested that the Centre should consider having an expert member on the Intellectual Property Appellate Board (IPAB) that reviews decisions of the Indian patent |
|
|
|
| Novartis optimistic despite Glivec setback | 19-JAN-08 |
|
| Swiss pharmaceutical giant Novartis is buoyant about growth prospects and further protection of intellectual property rights in India, despite the setback it suffered in the patent dispute for its |
|
|
|
|
|
|
| Novartis loses plea on patent board member | 21-JUL-07 |
|
| The Intellectual Property Appellate Board (IPAB) today dismissed Novartiss petition seeking a new member in place of former Patent Controller S Chandrasekhar to hear its appeal on the denial of an |
|
|
|
| IPAB rejects Novartis plea for new tech member | 20-JUL-07 |
|
| Intellectual Property Appellate Board (IPAB) has dismissed the application by pharma major Novartis to appoint a new technical member in place of former Patent Controller S Chandrasekhar to hear its |
|
|
|
| Glivec case deferred to July 10 | 02-JUL-07 |
|
| The Intellectual Property Appellate Board (IPAB), which is hearing the appeal against the Indian patent offices decision to not allow patent protection for Swiss drug maker Novartiss |
|
|
|
| Patents body seeks Novartis feedback on Glivec EMR | 29-JUN-05 |
|
| The office of Controller of Patents & Designs has completed the first examination of patent application filed by multinational Novartis AG for its blockbuster drug Glivec (imatinib mesylate). The |
|
|
|
| Maruti magic | 19-MAY-04 |
|
| Maruti Udyog has reported great results for the year ended March 2004, the first full-year number it has announced as a listed company. Income from operations was up 31.3 per cent, while profit before |
|
|
|
| Novartis plans to revive Gilvec aid programme | 17-NOV-03 |
|
| Swiss drug multinational Novartis, which got a five-year exclusive marketing right for its block-buster anti-cancer drug Glivec (imanitib mesylate) in India, is reviewing the option of restarting its |
|
|
|
| Glivec glitch | 14-NOV-03 |
|
| The first EMR in the Indian pharma sector has been shrouded in controversy.
|
|
|
|
| Novartis bags first EMR in India | 13-NOV-03 |
|
| Novartis India announced that it has been granted exclusive marketing rights (EMR) by the Controller General of Patents and trademarks of India for its blockbuster anti-cancer drug Glivec (imatinib |
|
|
|
Content Guide
